Background/Aims: MicroRNA-21 is an oncogenic miR (oncomiR) frequently elevated in gastric cancer (GC). Overexpression of miR-21 decreases the sensitivity of GC cells to 5-fluorouridine (5-Fu) and trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2). Receptor-mediated endocytosis plays a crucial role in the delivery of biotherapeutics including anti-miRNA oligonucleotides (AMOs). This study is a continuation of earlier findings involving poly(ε-caprolactone) (PCL)-poly (ethylene glycol) (PEG) nanoparticles (PEG-PCL NPs), which were coated with trastuzumab to target GC with HER2 receptor over-expression using anti-miRNA-21 (AMO-21) and 5-Fu. Methods: HER-PEG-PCL NPs were prepared by one-step carbodiimide coupling using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAc) and Sulfo-NHS in aqueous phase. Covalent coupling of amino groups at the surface of PEG-PCL with the carboxyl groups of trastuzumab was analyzed by X-ray photoelectron spectroscopy (XPS). AMO-21/5-Fu NPs were formulated by a double-emulsion solvent evaporation technique. The cell line specificity, cellular uptake and AMO-21 delivery were investigated through the rhodamine-B- 
Introduction
Gastric cancer (GC) ranks fourth among all cancers in worldwide incidence. It ranks second in cancer-related deaths reported in China [1] . Most patients are diagnosed with surgically advanced or metastatic disease [2] that require chemotherapy. The most commonly used chemotherapeutic agent for the treatment of GC is 5-Fu, but the response rate of this single agent chemotherapy is only about 11% [3] . Approximately 7% to 34% of gastric cancers are characterized by poor prognosis associated with amplification HER2 [4] [5] [6] . Treatment with a combination of trastuzumab (a humanized monoclonal antibody against HER2) and 5-Fu is indicated for HER2-positive advanced GC. Despite a significant survival advantage with the combination treatment, 12% of all HER2-positive GC cases show cancer progression [7] .
MicroRNAs (miRs) are well known for suppression of translation via RNA-induced silencing complex (RISC) [8] . Changes in miRNA expression profile is correlated with tumor pathogenesis, cancer progression, and drug resistance [9] . Therefore, AMOs facilitate tumor therapy by abrogating the expression of specific miRs [10] [11] [12] [13] . Down-regulation of miR-21, a gastric oncomiR, not only enhances the sensitivity of HER2-positive GC in vitro, in response to trastuzumab by regulating the miR-21 targeting gene PTEN [14] , but also the sensitvity of 5-Fu by regulating the miR-21 targeting gene Sprouty2 [15] . Thus, targeted AMO-21 delivery improves the efficacy of trastuzumab and 5-Fu simultaneously.
However, AMO is sensitive to nucleases. It is hydrophilic with poor membrane permeability. The stability and efficiency of AMO therapy is increased by treatment with 2'-O-methyl or 2'-O-methoxyethyl agents [16] . The modifications may reduce the specificity and affinity for the target miRNAs [17] , interfering with the efficient delivery of AMOs into cells. Therefore, enhancing the delivery of AMO using effective carrier vectors or Lipofectamine 2000 has been shown to be effective in proof-of-concept experimental studies. Nevertheless, viral vectors are potentially oncogenic, triggering immune response, inducing viral mutations and possess limited loading capacity [18] . Lipofectamine 2000 is potentially cytotoxic, non-specific for tissues, and is sensitive to serum proteins [18] . Safe and effective nonviral delivery systems are needed for clinically viable cancer treatment. Polymeric nanoparticle-based delivery is a promising strategy with high transfection efficiency. Polymeric nanoparticles are easily modified and functionally enhanced, and delivered safely without any toxicity [19] . Therefore, the design of a targeted nanoparticle system could overcomes the disadvantages of AMO effectively.
Nanodelivery systems have been shown to overcome the challenges posed by AMOs in therapeutic drug delivery in cancer using miRNA interference [20, 21] . The challenges of effective gene silencing relate to active recognition of target cells, without affecting normal cells [22] . Complexation of NPs with target-specific ligands or antibodies enhances therapeutic efficacy by facilitating targeted delivery to cancer cells [23, 24] . Based on the previous studies, trastuzumab was conjugated with poly(ethyleneglycol) (PEG) and poly(ε-caprolactone) (PCL) copolymers [25] , using PEG as the linker molecule (HER-PEG-PCL). Receptor mediated targeting of GC cells was accomplished by overexpressing HER2, using precision engineering of nanoparticles of biodegradable copolymers to quantitatively control AMO-21 and 5-Fu delivery (Fig. 1a) . The approach enhances the targeting by trastuzumab as well as ADCC of immune effector cells and the sensitivity of 5-Fu. The surface ligand density of molecules has been contorlled by using copolymers and trastuzumab in therapeutically effective ratios. The AMO-21 and 5-Fu were co-delivered targetedly by HER-PEG-PCL (AMO-21/5-Fu TNPs) to GC cells overexpressing NUGC4 and not SGC7901. The AMO-21-loaded PEG-PCL nanoparticles (AMO-21/5-Fu NPs) that failed to target HER2, and Lipofectamine 2000 were used as controls. It was hypothesized that trastuzumab combined with AMO-21 and 5-Fu was a promising therapeutic strategy for cancer. Enhanced trastuzumab and 5-Fu cytotoxicity in GC are mediated by the antagonism of target miR-21 against increased expression of PTEN and Sprouty2 respectively. Thus, multifunctional nanoparticles may represent a generalized approach for the treatment of GC.
Materials and Methods

Synthesis of PEG-PCL and HER-PEG-PCL copolymers
The PEG-PCL copolymers were prepared via ring opening copolymerization as described previously [25] . A single-step carbodiimide coupling with EDAc and Sulfo-NHS in aqueous phase was used to develop conjugates of trastuzumab [23] . Briefly, the stock solution (1 mg/mL) was prepared by diluting trastuzumab in borate buffer (pH 8.4). Dry PEG-PCL NPs was incubated with trastuzumab in borate buffer and supplemented with EDAc and Sulfo-NHS. The free primary amino groups on the NPs surface were conjugated with the carboxylic groups on the antibodies. After incubation overnight at room temperature under gentle end-to-end mixing, followed by centrifugation, the NPs were obtained. NPs were washed twice with borate buffer. The pellets were treated with ultrapure water for further analysis. The supernatant was
Surface chemistry
The presence of trastuzumab on NPs surface was determined by XPS. The NPs surface was further analyzed in terms of the specific binding energy (eV) of the elements. The eV was recorded from 0 to 1000 eV, with pass energy of 80 eV under fixed transmission. Nitrogen was analyzed under fine mode with 0.5 eV. The data were processed using specific XPS software.
Size, surface charge, encapsulation and drug loading measurement efficiency
The size, dispersity, zeta potential, and morphology of NPs were determined. Dynamic light scattering (DLS) (Brookhaven Instruments Corporation, USA) was employed to measure the hydrodynamic size and polydispersity. Zeta potential was measured using Zetaplus (Brookhaven Instruments Corporation, USA). The samples were stored at 37 °C in PBS. The morphology of NPs was analyzed using transmission electron microscopy (TEM, JEM-100S, JEOL, Japan). A single drop of diluted NP suspension on a copper grid covered with nitrocellulose membrane was air-dried at room temperature and negatively stained with phosphotungstic sodium solution (1% w/v). Encapsulation efficiency (EE) and drug loading content (DLC) of AMO-21 were determined [26] . In brief, AMO-21/5-Fu NPs (15 mg) were dissolved in dichloromethane (0.5 mL) at room temperature for 30 min, followed by extraction of AMO-21 from the organic phase using twice the volume of TE buffer (10 mM Tris e HCl, 1 mM EDTA , pH 7.4). After vortexing vigorously, the mixture was centrifuged at 12, 000 rpm and 4ºC for 10 min. The AMO-21 level was analyzed using the QuantiT TM , PicoGreen TM assay according the manufacturer' s instructions (Invitrogen, USA). The EE and DLC of 5-Fu were analyzed by High Performance Liquid Chromatography (HPLC) system (Agilent 1200 HPLC system, Agilent Technologies, Palo Alto, USA) as previously described. Chromatographic separation was achieved using a C18 reversed phase column (250 mm × 4.6 mm, 5 μM, ZORBAX Eclipse XDB-C18, Agilent Technologies, Palo Alto, USA) as the stationary phase. The mobile phase for 5-FU included sterile degassed methanol:water (10:90 v/v) with an injection volume of 20 μL and a flow rate of 0.8 mL/ min. This was held in an isocratic mode for 6 min at a wavelength of 265 nm using a UV detector. The retention time of 5-Fu was approximately 2.1 min.
The DLC and EE were calculated by the following equations: Cell culture NUGC4, NCI-N87, SGC7901 and BGC823 were supplied by American Type Culture Collection (ATCC). HER2 expression level in the cells was evaluated by western blot and immunohistochemistry as previously described [29] . HER2 was expressed positively in NCI-N87 and NUGC4 cells, and negatively in SGC7901 and BGC823 (Fig. 2a) , consistent with previous studies [14, 30] . The expression level of Sprouty2 was found lower in NUGC4 GC cells while higher in SGC7901 (Fig. 2b) . The miR-21 expression in the cells showing HER2-positive expression was determined by RT-PCR [14] . The expression of miR-21 was higher in NUGC4 SGC7901 than in NCI-N87 BGC823 cells (Fig. 3) , which were therefore, selected for further study. All cells were cultured in RPMI 1640 medium, supplemented with 10% fetal bovine serum and incubated at 37 °C at 5% CO2 and 95% humidity.
Cellular uptake by fluorescence microscopy Rhodamine B-labeled particles were reacted with hydroxyl group in HER-PEG-PCL and PEG-PCL copolymers as previously described [31] . This Rhodamine B labeled NPs were then loaded with FAM-labeled AMO-21 (FAM-AMO-21) and the fluorescent signals Rhodamine-B (red) and FAM (green) respectively tracked the location of NPs and AMO-21 in NUGC4 and SGC7901 cells. Cells were loaded in 6-well plates at a density of 2×10 5 cells/well and incubated overnight. An additional incubation for 2 hours was performed 
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Cellular Physiology and Biochemistry using a fixed concentration of FAM-AMO-21-loaded Rhodamine B-labeled HER-PEG-PCL and PEG-PCL NPs. The cells were washed three times with PBS, and fixed with 4% paraformaldehyde (PFA) for 30 min at room temperature. Following another round of washing the media were replaced with fresh culture media. The fluorescence was determined using an Olympus LX71 epifluorescence microscope (Olympus, Tokyo, Japan). For quantification, the color change in the PEG-PCL and HER-PEG-PCL groups was detected by the naked eye and analyzed using image analysis software (ImageJ). The integrated optical density (IOD) was used to quantify the fluorescence. The IOD of Rhodamine B and FAM were evaluated by performing tests under identical experimental conditions, in triplicate.
In vitro cytotoxicity of AMO-21/5-Fu TNPs
The cytotoxic potential of NPs was evaluated by MTT assay as previously described [32] . V is the absolute tumor volume, and V0 was the average tumor volume of the group on Day 1.
Real-time reverse-transcription polymerase chain reaction (RT-PCR)
Saline controls of NUGC4 cells were prepared. The cells were also treated with AMO formulations (free AMO-21, AMO-21-NPs, AMO-21/5-Fu-NPs, AMO-21-Lipofectamine 2000, AMO-21/5-Fu-NPs, AMO-21/5-Fu-TNPs) and incubated for an additional 2 days. The total RNA was extracted from the cells using an RNA isolation kit (Tian Gen) as per manufacturer's protocol and stored at -70°C for the use of RT-PCR. The mRNA transcripts were measured with reference to RUN6B, using a SYBR Green qRT-PCR miRNA Detection Kit (TianGen, Bejing, China) and SYBR Green I according to the manufacturer's protocols [33] . SYBR Green qRT-PCR was performed to measure mRNA expression levels of PTEN and Sprouty2. Beta-actin (ACTB) was used as an internal control [34, 35] . All of the primers are listed in Table 1 . The results were analyzed using the 2 (−ΔΔCT) comparative method [36] . All experiments were carried out in triplicate.
Statistical analysis
All the experiments were performed in triplicate. Continuous variables were expressed as the mean ± SD. A Student's t-test was used to compare the differences between groups. A P value that was less than 0.05 indicated statistical significance.
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Results
Preparation of HER-PEG-PCL copolymer
A single-step carbodiimide technique was employed to synthesize HER-PEG-PCL copolymers. The method was based on the PEG-PCL synthesized as described in the first part of Materials and Methods (Synthesis of PEG-PCL and HER-PEG-PCL copolymers).
Activation of carboxyl groups on the antibody molecules was followed by reaction with the primary amino groups on the PEG-PCL chains. The resulting amide bonds link the antibodies on the NPs surface. The antibody conjugation of NPs was confirmed by analyzing their surface chemistry using XPS to identify the changes in nitrogen signal according to the specific binding energy. Trastuzumab containing 1726 nitrogen atoms emits stronger signals than the amino groups in the PEG-PCL molecules. Distinct signal peaks emitted from nitrogen (N 1s) suggests antibody conjugation in the polymeric matrix cores ( Fig. 4a) .
Ligand surface density
The relationship between antibody conjugates on the NPs surface with the PEG-PCL-totrastuzumab ratio was investigated as described priviously [37] . A series of weight ratios (w/w) of PEG-PCL/trastuzumab 20%, 40%, 60% and 80% were used to prepare HER-PEG-PCL copolymers. The final levels of trastuzumab conjugated to the NPs surface were: 0.087, 0.216, 0.239, and 0.228 mg per mg of NPs after subtracting the background levels using 0% NPs as control (Table 2) . Therefore, 40% weight ratio (w/w) of PEG-PCL/trastuzumab was selected to synthesize HER-PEG-PCL copolymers for all subsequent experiments.
Preparation and characterization of AMO-21/5-Fu-loaded nanoparticles
AMO-21-NPs, AMO-21/5-Fu-NPs, AMO-21-TNPs, 5-Fu-TNPs and AMO-21/5-Fu-TNPs were synthesized using a double-emulsion solvent evaporation technique as described earlier.
NPs devoid of drug served as controls (NPs control). The average NPs ranged from 186.3 to 233.3 nm in size, which facilitated the enrichment of NPs in the tumor tissue by increasing the permeability and retention (EPR) [38] . The zeta potentials were negative, ranging from -9.11 mV to -13.13 mV, and the polydispersity ranged from 0.142 to 0.262 (Table 3) . TEM ( 
In vitro release and Cellular uptake
The in vitro release profiles of 5-Fu and AMO-21 from TNPs were investigated. 5-Fu presented a burst release from TNPs in the first 20 hours, with nearly 75% drug released from the carriers. After that, a steady sustained release was observed during the following 100 hours. The release speed of AMO-21 was similar to 5-Fu, with nearly 65% in the first 24 hours (Fig. 4c) .
The cellular uptake of HER-PEG-PCL nanoparticles based on HER2 expression was investigated. The rhodamine-labeled FAM-AMO-21-TNPs and FAM-AMO-21-NPs were used to track the position of nanoparticles and AMO-21. As shown in Fig. 5a , b, HER2-overexpressing NUGC4 cells were used as a positive control to compare the SGC7901 cells with negative HER2 expression. In SGC7901 cells, the IOD of Rhodamine B and FAM did not differ significantly between groups (PEG-PCL, HER-PEG-PCL) (P > 0.05). However, the IOD of Rhodamine B and FAM in the HER-PEG-PCL group were significantly higher than the PEG-PCL group in NUGC4 cells (P < 0.001) (Table 4) . Moreover, the IOD of Rhodamine B and FAM in the PEG-PCL group indicated similar cellular uptake in both NUGC4 and SGC7901 GC cells (P > 0.05) ( Table 5 ). The fluorescence intensity of PEG- PCL was similar to HER-PEG-PCL in SGC7901 cells. However, the fluorescence intensity of HER-PEG-PCL was stronger than that of PEG-PCL in NUGC4, suggesting effective targeting of HER-PEG-PCL nanoparticles into NUGC4 cells.
Table 4. Integrated optical density (IOD) of Rhodanmin-B-PEG-PCL, Rhodanmin-B-HER-PEG -PCL NPs, FAM-AMO-21-PEG-PCL NPs and, FAM-AMO-21-HER-PEG-
In vitro cytotoxicity
The in vitro antitumor activity of the formulations were analyzed in NUGC4 and SGC7901 cells after treatment with saline control, blank NPs, blank TNPs (equal trastuzumab concentration), trastuzumab (51µg/mL), 5-Fu (5µg/mL), 5-Fu-TNPs (equal 5-Fu and trastuzumab concentration), trastuzumab + 5-Fu, AMO-21 (100nmol/L) /5-FuNPs(equal 5-Fu and trastuzumab concentration), AMO-21(100nmol/L)/5-Fu-TNPs (equal 5-Fu and trastuzumab concentration) for 4 days using MTT assay. Cells treated with blank NPs exhibited maximum viability. It was similar to that of controls even after 4 days of incubation, suggesting absence of cytotoxicity (Fig. 6a, b) . NUGC4 cells treated with TNPs showed similar levels of cytotoxicity to trastuzumab. These cells showed higher cytotoxicity when treated with AMO-21/5-Fu-TNPs compared with 5-Fu + trastuzumab and AMO-21/5-Fu-NPs + trastuzumab (Fig. 6a) . In SGC7901 cells, the supression was not observed in the (Fig. 6b) .
In vivo antitumor activity of AMO-21/5-Fu-TNPs
The in vivo antitumor efficacy of PTX-SF-NPs was evaluated on the human gastric cancer NUGC4 nude mice xenograft model (Fig. 7) . In this study, blank NPs did not inhibit tumor growth. The tumors treated with TNPs and trastuzumab were significantly suppressed compared with those treated with saline (P < 0.01), but the differences between TNPs and trastuzumab were not significant (P > 0.05). The AMO-21-TNPs began to show an antitumor effect greater than that of trastuzumab after the first 7 days. The antitumor advantages of AMO-21/5-Fu-TNPs became more prominent as time passed (P < 0.05). AMO-21/5-Fu-TNPs completely halted tumor growth, and its antitumor effect was much higher than that of AMO-21/5-Fu-NPs + trastuzumab (P < 0.05). The tumors in the group treated with AMO-21/5-FuTNPs were the smallest among all groups (P < 0.05) (Fig. 7) . 1-fold, **P < 0.01) respectively. In contrast, no change in gene expression of free AMO-21 was found. In addition, the results indicated the superiority of TNP's over other transfection agents commercially available.
MiR-21 silencing, PTEN and Sprouty2 expression enhanced by AMO-21
Discussion
In this research, a novel trastuzumab-conjugated nanoscale drug delivery vehicle was prepared, with distinct therapeutic mechanisms based on the antibody per se (e.g., ADCC, CDC) and the carrier drugs of AMO-21 and 5-Fu. Therapeutic applications of trastuzumab conjugated with nanoparticles encapsulated with AMO-21 and 5-Fu against GC cells was initially demonstrated. The nanoparticle-based antibody conjugates not only increased the efficiency of targeting and AMO-21 transfection efficiency, but also sensitized the cancer cells to trastuzumab and 5-Fu resulting in effective tumor suppression.
MiRs control key genes involved in cancer and drug resistance [39] [40] [41] [42] . MiR-21 is a potential oncogenic miR involved in gastric cancer and is associated with trastuzumab and 5-Fu resistance [14, 15] . The miR overexpression is silenced by anti-miRs in a targeted manner [43] . AMO-21 was developed to specifically target miR-21. Traditional methods of oligonucleotide delivery are mediated via viruses and lipids such as Lipofectamine 2000 [44] . Modification of the oligonucleotide backbone also increases the stability of the miRs against enzymatic degradation and facilitates direct delivery to cells without the need for transfection. However, these methods are limited by their efficacy in vivo by serum nucleases, lysosomal degradation, and non-specific absorption [20] .
A nanoparticle-based delivery system improves stability and delivery efficiency. NPsbased delivery may be via active or passive targeting [45] . Passive targeting is facilitated by EPR or via localized application and delivery. Active targeting is accomplished by conjugating different targeting moieties with the surface of NPs [46] . Antibodies represent ideal anticancer agents. They have been the focus of intense research activity since the production of customized monoclonal antibody in the mid-1970s. However, antibodies have been used successfully as immunotargeting agents [47] . The strategy of this research employed tumor-cell-specific NPs conjugated with antibodies such as trastuzumab with the NP surface. It was previously reported that effective delivery of docetaxel and miRNA using PEG-PCL-based nanoparticles. PEG-PCL-based nanosystems targeted cancer cells and enhanced the cytotoxicity of docetaxel by sequence-specific gene silencing [26] . The current study developed nanoparticles of copolymers PEG-PCL conjugated with trastuzumab for targeted delivery of AMO-21. HER-PEG-PCL NPs were prepared using one-step carbodiimide coupling using EDAc and Sulfo-NHS in aqueous phase. Covalent coupling of amino groups at the surface of PEG-PCL with the carboxyl groups of trastuzumab was analyzed by XPS (Fig.  4a) . The formulation with the highest surface density of the ligand was further evaluated for the delivery of AMO-21 into GC cells. A herceptin-to-PEG-PCL mass ratio of 1:1 favored efficient conjugation ( Table 2 ). The free amino groups on the NPs surface provide linkers for the ligand molecules in the presence of EDAc. The increase in the number of amino groups in the PEG-PCL molecules increased the efficiency of covalent coupling. At a 50% ratio of PEG-PCL-to-trastuzumab, the binding efficiency was the highest. The NPs generated by doubleemulsion solvent evaporation method measured approximately 200 nm in size (Fig. 4b and Table 3) , with a negetive zeta potential conducive to cellular uptake via endocytosis [38] . A sustained release of AMO-21 in vitro suggests diffusion from the polymeric matrix of NPs for effective gene silencing (Fig. 4c ) . Meanwhile, the 5-FU release study also demonstrated a burst release be-havior following controlled-release ( Fig. 4c) ; Cytotoxic profiles were Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry similar for 5-FU + trastuzumab and single drug-loaded NPs (5-Fu-TNPs), suggesting that the triggering mechanism for the release of the drug from the NPs into the cytosols was highly efficient. Therefore, the data of this study confirm that TNP encapsulation not only aids in the stabilization of AMO-21 in the culture condition, which sustains its down-regulating effect, but also increases the efficiency co-administered with conventional chemotherapeutic drugs Nonspecific interaction between nanocarriers and non-target cells is a critical challenge that limits the therapeutic efficacy resulting in adverse effects [48] . The intracellular uptake of AMOs was monitored by the means of fluorescently-labeled AMO-21 and FAM-AMO-21 (green) encapsulated rhodamine B (red)-labeled HER-PEG-PCL NPs under fluorescence microscopy. FAM-AMO-21 was visualized in the cytoplasm of GC cells after transfection. Compared with PGE-PCL, the HER2 targeting ligand in the formulation contributed to improved cellular uptake, and enhanced transfection efficiency of NUGC4 cells (Fig. 5b) , via recognition of overexpressed surface antigens. Furthermore, the targeted uptake using HER2-negative cell line SGC7901 was established as a control. It was found that the cellular uptake of HER-PEG-PCL and PEG-PCL NPs was similar (Fig. 5a) . The reduced uptake level of FAM-AMO-21-TNPs in SGC7901 cells than in NUGC4 cells further confirmed that the entry of TNPs into GC cells was mediated by trastuzumab antibody-mediated endocytosis (Fig.  5a, b) . The cellular effect of the nanoformulation containing trastuzumab conjugated with nanocarriers was enhanced by active entry into cancer cells expressing HER2.
Trastuzumab conjugated with PEG-PCL NPs showed cytotoxic effects similar to free trastuzumab against NUGC4, which suggests that the antibody activity was retained even after nanoparticle synthesis. The AMO-21/5-Fu-TNPs showed a higher level of cytotoxicity compared with 5-Fu + trastuzumab (Fig. 6a) (Fig. 6b) , which showed a potential for reduced systemic toxicity while retaining efficacy against target cells. The efficacy of trastuzumab-conjugated NPs was higher and more direct compared with PEG-PCL NPs alone for HER2-positive cells, with less cytotoxicity for HER2-negitive cells. Therefore, increased anti-tumor effect in HER2-positive GC cells decreases the incidence of side effects. In vivo study, AMO-21/5-Fu-TNPs completely halted tumor growth, and its antitumor effect was much higher than other groups.
Compared with a commercial transfection agent lipofectamine 2000 and PEG-PCL NPs, the TNP encapsulating AMO-21 led to the efficient inhibition of miR-21 and an increase in PTEN and Sprouty2 expression in NUGC4 cells, while the treatment of free AMO-21, resulted in negligible change (Fig. 8a,b) .This suggests that the inhibition of miR-21 and subsequent increment in target genes can be attributed to the antagonism of miR-21 with AMO-21.
Reports investigating targeted PEG-PCL-based delivery combined with ligands for anti-miR delivery to GC are rare. In this study, it was reported that the synthesis of PEG-PCL NPs targeting HER2 for the delivery of AMO-21 and 5-Fu to GC cells. The TNPs showed favorable physicochemical properties and selective uptake by targeted cells. TNPs containing AMO-21 significantly enhanced target genes that are known to be repressed by miR-21. These findings suggest the potential application of anti-miR therapies in GC. These studies represent the initial step in AMO-21 and nanotechnology-based therapies against gastric cancer. In addition, the potential role of HER-PEG-PCL NPs to transfect AMOs, as well as therapeutic antibodies into cancer cells facilitates a multi-pronged strategy against Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry trastuzumab-resistant tumors. The efficacy of AMO-21 TNPs in targeting gastric tumors will be investigated in future studies.
Conclusion
We report the anticancer potential of a combination of 5-Fu treatment and AMO-21 technology using trastuzumab conjugated PEG-PCL copolymers, an available co-carrier of chemotherapeutant and AMO-21, could effectively deliver 5-FU and AMO-21 simultaneously, this trastuzumab-conjuctated nanoparticles effectively protected AMO-21 against nuclease degradation and suppressed the target miRNA expression in NUGC4 GC (HER2-expressing) cells and further up-regulated phosphatase and tensin homolog (PTEN) and Sprayt2. As a result, the sensitivity of GC cells to trastuzumab and 5-Fu was enhanced. The approach enhances the targeting by trastuzumab as well as antibody-dependent cellular cytotoxicity (ADCC) of immune effector cells. The co-delivery AMO-21 significantly improved the cytotoxicity of 5-Fu and trastuzumab to NUGC4 cells. Our results provide invaluable information regarding the future application of drug-polymer complexes combined with gene therapy for cancer treatments. Taken together, our findings suggest that the co-delivery of 5-Fu treatment and AMO-21 by HER-PEG-PCL nanoparticle might be a potential clinical strategy for gastric cancer chemotherapy.
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